2,3-dihydroquinazolin compounds as nav1.8 inhibitors

A compound represented by the following Formula (X):

• where:
• Y′ is selected from:
• CH2, C═O and C═S;
• X′ is N or C—R4′;
• wherein:
• R4′ is selected from:
• hydrogen, halogen, —C≡N, —NRaRb, straight or branched-(C1-6)-alkyl, —OR′ and —S(O)pRd,
• wherein, when R4′ is straight or branched —(C1-6)-alkyl or —ORc, the alkyl chain, when present, is optionally substituted with one to six substituents independently selected from:
• halogen, —C≡N, oxo, —NRaRb, straight or branched-(C1-6)-alkyl, straight or branched-(C1-6)-haloalkyl and —ORc;
• R1′, R2′ and R3′ are independently selected from:
• hydrogen, halogen, —C≡N, —NRaRb, straight or branched-(C1-6)-alkyl, carbocyclic, heterocyclic, bicycloalkyl, —OR′ and —S(O)pRd,
• wherein, when any of R1, R2′ and R3′ is a straight or branched-(C1-6)-alkyl, or —ORc, the alkyl chain, when present, is optionally substituted with one to six substituents independently selected from:
• halogen, —C≡N, —NRaRb, straight or branched-(C1-6)-alkyl, straight or branched-(C1-6)-haloalkyl, oxo and —ORc;
• R5′ is selected from:
• carbocyclic, —CH2-unsaturated carbocyclic, heterocyclic, or bicycloalkyl,
• wherein, R5′ is optionally substituted with from one to four substituents independently selected from:
• —C≡N, —NRaRb, halogen, oxo, —C(O)NHRa, —C(O)NRaRb, straight or branched-(C1-6)-alkyl, —ORc, and (C3-6)cycloalkyl,
• wherein each of:
• straight or branched-(C1-6)-alkyl, the alkyl chain of —ORc, when present, and (C3-6)-cycloalkyl is optionally substituted with one to six substituents independently selected from:
• halogen, oxo, —OH, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2, —OC1-4alkyl and —OC1-4alkyl substituted with from 1 to 6 substituents independently selected from:
• fluoro, oxo, —OH, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2, —OC1-3alkyl, and —OC1-3alkyl substituted 1 to 6 times by fluoro;
• R6′ is hydrogen, oxo, straight or branched-(C1-6)-alkyl or straight or branched-(C1-6)-haloalkyl;
• B′ is selected from:
• aryl, heterocycloalkyl, and heteroaryl;
• each R7′ is independently selected from:
• halogen, oxo, —C≡N, —NRaRb, —ORc, —S(O)pRd, straight or branched (C1-6) alkyl, bicycloalkyl and (C3-6)-cycloalkyl,
• wherein, when R7′ is a straight or branched —(C1-6)-alkyl, or —ORc, the alkyl chain, when present, is optionally substituted with one to three substituents independently selected from:
• halogen, —C≡N, —NRaRb, straight or branched-(C1-6)-alkyl, straight or branched-(C1-6)-haloalkyl, oxo and —ORc;
• Rd is hydrogen, —OH, —NRaRb, straight or branched-(C1-6)-alkyl, straight or branched-(C1-6)-haloalkyl or (C3-6)-cycloalkyl;
• in each occurrence, Ra, Rb and Rc are independently selected from:
• hydrogen, straight or branched-(C1-6)-alkyl, and (C3-6)-cycloalkyl,
• wherein each of:
• straight or branched-(C1-6)-alkyl, and (C3-6)-cycloalkyl is optionally substituted with one to six substituents independently selected from:
• halogen, oxo, —OH, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2, —OC1-4alkyl and —OC1-4alkyl substituted with from 1 to 6 substituents independently selected from:
• fluoro, oxo, —OH, —NH2, —NHC1-4alkyl, —N(C1-4alkyl)2, —OC1-3alkyl, and —OC1-3alkyl substituted 1 to 6 times by fluoro;
• z1′ is an integer from 0 to 5;
• and
• p is 0, 1 or 2;
• or a tautomer thereof,
• or a pharmaceutically acceptable salt thereof.